CFTR Modulators Associated with Improved Mental Health and Sleep in Children with CF and Their Caregivers Over 18 Months

Hande Yetişgin, Işıl Bilgiç, Meltem Kürtül Çakar, et al.

Summary: Researchers in Turkey followed 24 children with CF receiving CFTR modulator therapy — and their parents — for 18 months, using established questionnaires to measure anxiety, depression, sleep quality, and quality of life at the start and end of the study. By the end, children showed meaningful improvements in anxiety, depression, and daytime sleepiness. Their parents also reported lower depression, less anxiety, reduced caregiver burden, and better overall quality of life. Scores on a widely used CF quality-of-life measure improved in physical, social, and breathing-related areas for both children and parents.

Why it matters: Living with CF takes a heavy psychological toll on patients and families, and this aspect of the condition has historically received less attention than lung function. If CFTR modulators — which already help breathing and nutrition — also reduce anxiety and depression in children and ease the burden on caregivers, the case for making these medicines widely available becomes even stronger. This study followed people over 18 months, which is longer than most previous work on this question, and used well-recognized measurement tools.

What to keep in mind: With only 24 participants, all from a single hospital in Turkey, it is difficult to know how widely these findings apply. More importantly, the study had no comparison group — there were no CF patients followed over the same period without modulator therapy. Without that comparison, it is impossible to know how much of the improvement was caused by the medicine itself, and how much was due simply to the passage of time, the natural course of the disease, or the extra attention that comes with being in a study. Improvements in physical health over 18 months of treatment could also explain better mental health, independently of any direct effect of the medicine on the brain or mood. Larger studies involving multiple hospitals and a comparison group are needed before firm conclusions can be drawn about whether CFTR modulators directly improve mental health.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42576010/

---